Tango Therapeutics (TNGX)
(Delayed Data from NSDQ)
$8.50 USD
-0.41 (-4.60%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $8.49 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TNGX 8.50 -0.41(-4.60%)
Will TNGX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TNGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TNGX
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates
Amgen (AMGN) Expected to Beat Earnings Estimates: Should You Buy?
TNGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline
Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?
Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?
Other News for TNGX
Buy Rating Affirmed for Tango Therapeutics on Strong PRMT5 Program Progress and Solid Financials
Analyst Expectations For Tango Therapeutics's Future
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Inozyme Pharma (INZY) and Foghorn Therapeutics (FHTX)
Tango Therapeutics price target raised by $2 at Wedbush, here's why
Barclays Sticks to Its Buy Rating for Tango Therapeutics (TNGX)